Skip to main content

Table 1 Demographic and clinical characteristics of the study participants at baseline

From: The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study

Characteristic

Pramipexole ER

Pramipexole IR

Total

n=236

n=239

n=475

Age, mean (±SD) years

62.2(9.10)

61.8(9.03)

62.0(9.06)

  <65

140(59.8)

146(61.1)

286(60.5)

  ≥65

94(40.2)

93(38.9)

187(39.5)

Female sex, n (%)

80(34.2)

95(39.7)

175(37.0)

Body mass index, mean (±SD) kg/m 2

23.3(2.85)

23.3(3.06)

23.3(2.95)

Hoehn and Yahr stage, n (%)

   

  On phase

   

  2-3

226(96.6)

234(97.9)

460(97.3)

  4-5

8(3.4)

5(2.1)

13(2.7)

  Off phase

   

  2-3

113(48.3)

119(49.8)

232(49.0)

  4-5

18(7.7)

18(7.5)

36(7.6)

  Missing

103(44.0)

102(42.7)

205(43.3)

UPDRS score, mean (±SD)

   

  II

13.0(4.92)

13.0(5.97)

13.0(5.47)

  III

31.7(12.09)

32.1(12.78)

31.9(12.43)

  II+III

44.7(15.69)

45.1(17.31)

44.9(16.51)

PD stage, n (%)

   

  Early

122(52.1)

133(55.6)

255(53.9)

  Advanced

112(47.9)

106(44.4)

218(46.1)

Duration of disease, mean (±SD) years

5.11(3.33)

4.82(3.09)

4.96(3.21)

  2 to <5, n (%)

146(62.4)

153(64.0)

299(63.2)

  ≥5, n (%)

88(37.6)

86(36.0)

174(36.8)

MMSE score, mean (±SD)

28.4(1.61)

28.4(1.44)

28.4(1.52)

ESS score, mean (±SD)

5.0(3.81)

5.4(4.13)

5.2(3.97)

  1. EES, Epworth sleepiness scale; MMSE, Mini Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale.
  2. The chi-square test was used for categorical variables, and one-way analysis of variance for continuous variables. There were no significant between-group differences in any baseline characteristics.